AOPharma choses 4ID to continue the development of its next product generation
Following the successful completion of their Proof of Concept model – AOPharma Ltd. has chosen 4ID to continue the development of its next product generation of the Eye AdMisterTM.
"We are excited and proud to be a part of this truly necessary and fascinating product development, we plan to take the company’s vision and turn it into a working device to help millions of people around the world deal with administering eye drops , says Josh Altman, 4ID's CEO.
"We have full confidence in 4ID's ability to complete this mission successfully and we are looking forward to introduce our Multi-Dose & Preservative free drug delivery system to the market says Keren Leshem AOPharma’s General Manager. 
AOPharma Ltd. , an Ophthalmic Pharmaceutical company, has successfully completed a $2 million investment round raised from investors including Coronis Partners – an Investment Company specialized in the Biotechnology sector, Mr. Gur Munzer, owner of Care Medical Services and of Natalie and the Rad BioMed Incubator owned by Mr. Yehuda Zisapel in associations with Israel’s Chief Scientist. To date the company has raised over three million dollars.
AOPharma develops unique and innovative technologies targeting the continually growing Ophthalmic Pharmaceutical market; estimated to reach over $13 billion per year.
Links:
Globes
The Marker (Hebrew)
March 23rd, 2010, Tel-Aviv.
